Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for (Study ST002634)

HILIC POSITIVE ION MODE (Analysis AN004306)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12	F13
allantoin	ME624351	0.89	0.92	1.00	1.05	1.24	1.08	0.98	1.00	1.06	0.84	0.99	0.84	0.97
beta-guanidinopropionate	ME624360	1.10	1.02	1.09	1.06	0.70	1.15	0.79	1.16	0.85	1.35	0.91	1.01	1.04
1-methylnicotinamide	ME624332	1.11	1.00	1.07	1.05	0.76	1.29	0.98	1.34	1.05	0.89	0.93	0.80	0.90
acetylcholine	ME624344	0.84	0.85	1.08	1.07	0.71	1.39	1.15	1.42	1.22	0.84	1.04	0.80	0.80
4-acetamidobutanoate	ME624339	0.90	1.00	1.06	1.01	1.04	1.12	0.96	1.06	0.98	1.00	0.98	0.88	1.00
4-guanidinobutanoate	ME624340	1.08	1.11	1.02	1.01	0.75	1.05	0.97	1.03	0.99	1.06	1.11	1.04	0.94
ala-ala	ME624349	1.07	0.67	1.00	1.01	1.16	1.41	0.78	1.16	0.97	0.73	1.28	1.06	0.61
betaine	ME624361	1.02	0.93	1.02	1.02	1.06	1.15	0.90	1.02	1.02	1.06	0.86	1.01	0.90
acisoga	ME624345	0.88	0.83	0.95	0.95	1.74	1.56	0.79	1.23	0.83	0.81	0.73	0.74	0.49
arachidoyl ethanolamide	ME624355	0.87	0.60	0.82	0.86	1.22	1.68	0.80	0.84	1.42	1.04	1.34	0.40	0.89
5-methylcytosine	ME624342	1.40	0.61	1.14	1.12	0.41	1.63	0.63	1.45	0.60	1.37	0.79	1.46	0.80
anserine	ME624354	0.75	1.03	1.02	1.02	1.15	0.91	1.05	0.85	1.31	0.77	1.36	0.66	1.03
arginine	ME624356	0.98	1.09	1.03	1.03	1.07	0.97	0.92	0.99	1.01	0.98	0.98	0.91	1.01
C10 carnitine	ME624375	1.05	1.13	1.03	0.99	1.11	0.88	1.10	0.82	1.13	0.87	1.09	0.79	0.96
2^-O-methyladenosine	ME624336	1.17	1.18	0.90	0.93	1.78	0.72	0.73	0.74	0.64	1.01	0.73	0.98	0.98
alanine	ME624350	0.90	1.05	1.03	1.02	1.02	1.08	1.03	1.03	1.00	0.91	0.99	0.92	1.02
5-methylcytidine	ME624341	0.94	1.03	1.06	1.02	0.90	1.08	1.03	1.10	1.05	0.86	1.02	0.95	1.04
ADMA	ME624347	1.00	1.13	1.02	1.03	1.03	1.08	0.99	1.04	1.04	0.89	1.01	0.84	0.88
21-deoxycortisol	ME624333	0.58	0.44	0.70	0.73	2.33	0.76	1.34	0.77	1.04	0.80	1.38	0.24	0.98
3-methoxytyramine	ME624337	1.47	0.62	0.73	1.19	1.09	0.75	0.70	0.82	0.96	1.66	1.08	1.16	0.66
beta-alanine	ME624359	0.90	1.02	1.05	1.06	0.93	1.09	1.01	1.03	1.03	1.01	1.02	0.91	1.01
7-methylguanine	ME624343	1.00	0.99	1.01	0.96	1.08	1.12	0.93	1.05	0.94	0.97	0.97	1.00	0.92
adenosine	ME624346	1.12	1.17	1.04	1.03	1.07	0.87	0.97	0.93	0.87	0.96	0.87	1.02	1.06
alloisoleucine	ME624352	1.01	1.00	1.04	1.04	0.91	1.10	1.00	1.09	1.01	1.03	0.99	0.94	0.91
aspartate	ME624358	0.97	1.01	1.03	1.02	1.00	1.02	0.93	1.05	1.04	0.99	1.11	0.89	0.95
1-methylhistamine	ME624331	1.08	0.80	1.02	1.04	0.96	0.98	0.80	1.29	0.98	1.51	0.88	0.82	0.87
2^-deoxyadenosine	ME624334	1.13	1.16	0.97	0.97	1.53	0.81	0.89	0.87	0.78	0.96	0.79	0.90	0.91
agmatine	ME624348	0.10	0.11	1.05	1.02	0.59	9.78	0.08	0.11	0.09	0.07	0.10	0.09	0.06
asparagine	ME624357	0.92	1.03	1.03	1.01	1.08	1.05	1.03	1.07	1.04	0.95	0.96	0.87	0.93
1-methyladenosine	ME624330	0.93	1.04	1.02	1.00	1.05	1.09	1.05	1.04	1.01	0.91	0.95	0.93	0.95
butyrobetaine	ME624363	0.96	1.00	1.05	1.04	0.90	1.09	1.01	1.09	1.03	0.94	1.06	0.93	0.98
2^-deoxycytidine	ME624335	0.93	1.14	1.06	1.06	0.76	1.04	1.12	1.01	1.15	0.86	1.12	0.89	1.03
C12:1 carnitine	ME624377	1.15	1.17	1.07	1.06	0.90	1.13	1.14	0.88	1.04	0.89	0.91	0.83	0.92
biliverdin	ME624362	0.66	1.08	0.97	1.02	1.36	1.00	0.71	1.12	1.17	0.78	1.04	0.59	1.31
3-methylhistidine	ME624338	0.65	1.28	1.00	1.01	1.13	0.84	1.20	0.80	1.33	0.63	1.37	0.57	1.14
alpha-glycerophosphocholine	ME624353	0.95	0.95	1.02	1.02	1.05	1.02	0.96	1.04	1.00	1.06	1.03	0.87	0.99

Factors:

F1	Group:Control \| Timepoint:8 weeks of training or control time \| Sex:Female
F2	Group:Control \| Timepoint:8 weeks of training or control time \| Sex:Male
F3	Group:QC-DriftCorrection \| Timepoint:0 hour \| Sex:-
F4	Group:QC-Pooled \| Timepoint:0 hour \| Sex:-
F5	Group:QC-Reference \| Timepoint:0 hour \| Sex:-
F6	Group:Training \| Timepoint:1 week of training or control time \| Sex:Female
F7	Group:Training \| Timepoint:1 week of training or control time \| Sex:Male
F8	Group:Training \| Timepoint:2 weeks of training \| Sex:Female
F9	Group:Training \| Timepoint:2 weeks of training \| Sex:Male
F10	Group:Training \| Timepoint:4 weeks of training \| Sex:Female
F11	Group:Training \| Timepoint:4 weeks of training \| Sex:Male
F12	Group:Training \| Timepoint:8 weeks of training or control time \| Sex:Female
F13	Group:Training \| Timepoint:8 weeks of training or control time \| Sex:Male

Data matrix